12
Participants
Start Date
October 16, 2024
Primary Completion Date
April 9, 2027
Study Completion Date
April 9, 2027
EXG110 injection
EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
RECRUITING
Shanghai Children's Medical Center, Shanghai
RECRUITING
Children's Hospital, Zhejiang University School of Medicine, Hangzhou
The Children's Hospital of Zhejiang University School of Medicine
OTHER